HRP20171648T1 - Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze - Google Patents

Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze Download PDF

Info

Publication number
HRP20171648T1
HRP20171648T1 HRP20171648TT HRP20171648T HRP20171648T1 HR P20171648 T1 HRP20171648 T1 HR P20171648T1 HR P20171648T T HRP20171648T T HR P20171648TT HR P20171648 T HRP20171648 T HR P20171648T HR P20171648 T1 HRP20171648 T1 HR P20171648T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
compound according
ghrelin
Prior art date
Application number
HRP20171648TT
Other languages
English (en)
Inventor
Maria Angeles Martinez-Grau
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171648T1 publication Critical patent/HRP20171648T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (10)

1. Spoj, naznačen time što je spoj formule [image] ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule [image] ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je spoj formule [image]
4. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegovu farmaceutski prihvatljivu sol, kao i jednu ili više farmaceutski prihvatljivih podloga, razrjeđivača ili pomoćnih tvari.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što sadrži jedno ili više drugih terapijskih sredstava.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u smanjivanju povećanja težine.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u smanjivanju ponovnog povećanja težine.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju pretilosti.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju dijabetesa tip 2.
HRP20171648TT 2013-11-14 2017-10-27 Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze HRP20171648T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382460 2013-11-14
EP14802755.0A EP3068775B1 (en) 2013-11-14 2014-11-06 Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
PCT/US2014/064202 WO2015073281A1 (en) 2013-11-14 2014-11-06 Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor

Publications (1)

Publication Number Publication Date
HRP20171648T1 true HRP20171648T1 (hr) 2017-12-15

Family

ID=49622771

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171648TT HRP20171648T1 (hr) 2013-11-14 2017-10-27 Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze

Country Status (40)

Country Link
US (1) US9035051B1 (hr)
EP (1) EP3068775B1 (hr)
JP (1) JP6159484B2 (hr)
KR (1) KR101739243B1 (hr)
CN (1) CN105636948B (hr)
AP (1) AP2016009189A0 (hr)
AR (1) AR098274A1 (hr)
AU (1) AU2014348967B2 (hr)
BR (1) BR112016009488B1 (hr)
CA (1) CA2926224C (hr)
CL (1) CL2016001023A1 (hr)
CR (1) CR20160184A (hr)
CY (1) CY1119489T1 (hr)
DK (1) DK3068775T3 (hr)
DO (1) DOP2016000070A (hr)
EA (1) EA028550B1 (hr)
ES (1) ES2647790T3 (hr)
HK (1) HK1222860A1 (hr)
HR (1) HRP20171648T1 (hr)
HU (1) HUE035590T2 (hr)
IL (1) IL244856A (hr)
JO (1) JO3302B1 (hr)
LT (1) LT3068775T (hr)
MA (1) MA39025B1 (hr)
ME (1) ME02841B (hr)
MX (1) MX2016006223A (hr)
NO (1) NO3068775T3 (hr)
NZ (1) NZ718373A (hr)
PE (1) PE20160609A1 (hr)
PH (1) PH12016500895A1 (hr)
PL (1) PL3068775T3 (hr)
PT (1) PT3068775T (hr)
RS (1) RS56533B1 (hr)
SG (1) SG11201602953YA (hr)
SI (1) SI3068775T1 (hr)
TN (1) TN2016000145A1 (hr)
TW (1) TWI538677B (hr)
UA (1) UA118034C2 (hr)
WO (1) WO2015073281A1 (hr)
ZA (1) ZA201602202B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104673A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MY197064A (en) 2016-08-05 2023-05-24 Boehringer Ingelheim Int Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CN106478519B (zh) * 2016-10-10 2018-12-11 上海再启生物技术有限公司 一种2-甲基-4-氨基-6-氯嘧啶的制备方法
JOP20200187A1 (ar) * 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
JOP20200190A1 (ar) 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat)
US11319310B2 (en) 2018-02-02 2022-05-03 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
CN108610337A (zh) * 2018-05-30 2018-10-02 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108558852A (zh) * 2018-05-30 2018-09-21 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN108774221A (zh) * 2018-05-30 2018-11-09 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN108516971A (zh) * 2018-05-30 2018-09-11 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108558849A (zh) * 2018-05-30 2018-09-21 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070708A1 (en) * 2000-03-23 2001-09-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2005026211A2 (en) 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
JP2008515771A (ja) 2004-07-14 2008-05-15 イーライ リリー アンド カンパニー 抗グレリン抗体
WO2006055347A2 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
ATE466289T1 (de) 2005-01-26 2010-05-15 Kistler Holding Ag Masseisolierter piezoelektrischer sensor zur messung von beschleunigung oder druck
EP1856154A1 (en) 2005-02-23 2007-11-21 Eli Lilly And Company Humanized anti-ghrelin antibodies
JP4975739B2 (ja) * 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
CN101175759A (zh) * 2005-05-17 2008-05-07 先灵公司 作为治疗血脂异常的烟酸受体激动剂的杂环化合物
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
US8129376B2 (en) * 2008-03-20 2012-03-06 Sundaresan Kumar Piperidine derivatives as inhibitors of stearoyl-CoA desaturase
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida

Also Published As

Publication number Publication date
HK1222860A1 (zh) 2017-07-14
CA2926224C (en) 2017-05-02
EA201690764A1 (ru) 2016-07-29
US9035051B1 (en) 2015-05-19
UA118034C2 (uk) 2018-11-12
AR098274A1 (es) 2016-05-18
KR20160068926A (ko) 2016-06-15
CN105636948A (zh) 2016-06-01
HUE035590T2 (en) 2018-05-28
BR112016009488B1 (pt) 2021-01-19
WO2015073281A1 (en) 2015-05-21
AU2014348967B2 (en) 2017-05-04
TN2016000145A1 (en) 2017-10-06
LT3068775T (lt) 2017-11-27
PT3068775T (pt) 2017-11-20
JP2016537371A (ja) 2016-12-01
NZ718373A (en) 2017-12-22
MX2016006223A (es) 2016-08-08
PE20160609A1 (es) 2016-07-03
CL2016001023A1 (es) 2016-11-18
PL3068775T3 (pl) 2018-01-31
IL244856A (en) 2017-07-31
EP3068775A1 (en) 2016-09-21
JP6159484B2 (ja) 2017-07-05
MA39025B1 (fr) 2018-05-31
ME02841B (me) 2018-01-20
CN105636948B (zh) 2017-10-24
TW201529073A (zh) 2015-08-01
CR20160184A (es) 2016-06-17
KR101739243B1 (ko) 2017-05-23
MA39025A1 (fr) 2017-05-31
ES2647790T3 (es) 2017-12-26
RS56533B1 (sr) 2018-02-28
TWI538677B (zh) 2016-06-21
SI3068775T1 (sl) 2017-10-30
ZA201602202B (en) 2019-10-30
NO3068775T3 (hr) 2018-02-03
PH12016500895B1 (en) 2016-06-20
EA028550B1 (ru) 2017-11-30
SG11201602953YA (en) 2016-05-30
AP2016009189A0 (en) 2016-05-31
EP3068775B1 (en) 2017-09-06
IL244856A0 (en) 2016-05-31
CA2926224A1 (en) 2015-05-21
PH12016500895A1 (en) 2016-06-20
JO3302B1 (ar) 2018-09-16
AU2014348967A1 (en) 2016-04-28
DOP2016000070A (es) 2016-05-30
CY1119489T1 (el) 2018-03-07
DK3068775T3 (en) 2017-10-23
US20150133474A1 (en) 2015-05-14
BR112016009488A8 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20171512T1 (hr) Derivati betulina
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
MD4736C1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
MX364400B (es) Compuestos de tetraciclina.
JP2015516419A5 (hr)
EA201692298A1 (ru) Производные карбоксамидов
UA117154C2 (uk) Антагоністи s1p3
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
HRP20171514T1 (hr) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt
MX2015018040A (es) Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.
BR112015010823A2 (pt) composto de 2-piridona
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EA201792170A1 (ru) Производные индола